首页 | 本学科首页   官方微博 | 高级检索  
     

第三代铂抗癌药物研究评论
引用本文:杨一昆,熊惠周.第三代铂抗癌药物研究评论[J].贵金属,1996,17(2):50-57.
作者姓名:杨一昆  熊惠周
作者单位:昆明贵金属研究所
摘    要:本文评论顺铂和卡铂之后的第三代铂抗癌药物的研究状况。报道其配合物的抗肿瘤活性、限量毒性、交叉耐药性和其中四种配合物的Ⅱ期临床结果。这些配合物的总体水平并不优于顺铂和卡铂。研究抗癌机理与顺铂和卡铂不同的新型铂配合物是增加该类药物的抗肿瘤活性和克服交叉耐药性的途径之一。

关 键 词:铂抗癌药,活性,毒性,交叉耐药性

Study on the Third Generation Platinum Anticancer Drugs
Yang Yikun,Xiong Huizhou,Pu Shaoping,Liu Weiping,Chen Xizhu,He Jian Institute of Precious Metals,Kunming.Study on the Third Generation Platinum Anticancer Drugs[J].Precious Metals,1996,17(2):50-57.
Authors:Yang Yikun  Xiong Huizhou  Pu Shaoping  Liu Weiping  Chen Xizhu  He Jian Institute of Precious Metals  Kunming
Affiliation:Yang Yikun,Xiong Huizhou,Pu Shaoping,Liu Weiping,Chen Xizhu,He Jian Institute of Precious Metals,Kunming 650221)
Abstract:The studies and clinical applications on the third generation platinum anticancer drugs following Cisplatin and Carboplatin have been reviewed in details.The antitumor activities,dose-limiting toxicities and cross-resistances of several Pt complexes which have entered into phase I clinical trials and phase II clinical of 4 of them are reported.It is indicated that the total levels of these complexes are not superior to Cisplatin and Carboplatin.Investigation on novel Pt complexes with different anticancer's mechanisms from Cisplatin and Carboplatin is one of ways to increase the anticancer activities of Pt drugs and to overcome their cross-resistances.
Keywords:Anticancer drugs  Platinum complexes  Activity  Toxicity  Cross-resistance  
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号